Key result
Hepatitis C virus translation is regulated by the internal ribosome entry site, canonical and alternative initiation factors, trans-acting factors, and liver-specific microRNA-122.
This review summarizes the complex molecular mechanisms regulating Hepatitis C virus translation, highlighting the roles of viral RNA structures and host factors.
Translation of the hepatitis C virus (HCV) RNA genome is regulated by the internal ribosome entry site (IRES), located in the 5’-untranslated region (5′UTR) and part of the core protein coding sequence, and by the 3′UTR. The 5′UTR has some highly conserved structural regions, while others can assume different conformations. The IRES can bind to the ribosomal 40S subunit with high affinity without any other factors. Nevertheless, IRES activity is modulated by additional cis sequences in the viral genome, including the 3′UTR and the cis-acting replication element (CRE). Canonical translation initiation factors (eIFs) are involved in HCV translation initiation, including eIF3, eIF2, eIF1A, eIF5, and eIF5B. Alternatively, under stress conditions and limited eIF2-Met-tRNAiMet availability, alternative initiation factors such as eIF2D, eIF2A, and eIF5B can substitute for eIF2 to allow HCV translation even when cellular mRNA translation is downregulated. In addition, several IRES trans-acting factors (ITAFs) modulate IRES activity by building large networks of RNA-protein and protein–protein interactions, also connecting 5′- and 3′-ends of the viral RNA. Moreover, some ITAFs can act as RNA chaperones that help to position the viral AUG start codon in the ribosomal 40S subunit entry channel. Finally, the liver-specific microRNA-122 (miR-122) stimulates HCV IRES-dependent translation, most likely by stabilizing a certain structure of the IRES that is required for initiation.
No takes yet. Share an insight, caveat, or question.
Niepmann et al. (2020) conducted a review in Hepatitis C Virus. Hepatitis C virus translation is regulated by the internal ribosome entry site, canonical and alternative initiation factors, trans-acting factors, and liver-specific microRNA-122.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: